MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Synairgen plc Company Profile (LON:SNG)

Consensus Ratings for Synairgen plc (LON:SNG) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 92

Analysts' Ratings History for Synairgen plc (LON:SNG)
Show:
DateFirmActionRatingPrice TargetActions
3/22/2016FinnCapReiterated RatingCorporateGBX 127 -> GBX 137View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016N+1 SingerReiterated RatingBuyGBX 47View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Synairgen plc (LON:SNG)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Synairgen plc (LON:SNG)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Synairgen plc (LON:SNG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/11/2015Shaw,Simon J BInsiderBuy65,217GBX 23£14,999.91Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Synairgen plc (LON:SNG)
DateHeadline
06/15/16 10:52 AMSynairgen : Results of 2016 Annual General Meeting
03/29/16 08:10 PMSynairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers -
03/22/16 06:07 AMFull Year 2015 Synairgen PLC Earnings Release - Before Market Open -
03/22/16 02:45 AMPositive LOXL2 results - [at noodls] - 7d8d7cd6-3c2e-47ac-8fc6-6e6407d3c882.pdf Analyst conference call An analyst briefing and conference call will take place today, Tuesday 22 March 2016, at 9:30am GMT to discuss the LOXL2 update and the ...
08/05/15 08:04 AMSynairgen plc - Synairgen and Pharmaxis announce research collaboration to develop LOXL2 inhibitor for pulmonary fibrosis - [at noodls] - Portfolio news 2015 05 Aug 2015 Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, and Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) today announced they have ...
08/04/15 11:02 PMPharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis - [PR Newswire] - SYDNEY and SOUTHAMPTON, England, Aug. 5, 2015 /PRNewswire/ -- Australian pharmaceutical company Pharmaxis Ltd (PXS.AX) and UK biotechnology company Synairgen plc (SNG.L) today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement Synairgen will fund further activity of the program at Pharmaxis, use its BioBank and in vitro lung model platform, and collaborate with the IPF research team at the University of Southampton to complete pre-clinical and early clinical development.
About Synairgen plc

Synairgen plc logoSynairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls). Using the BioBank, Synairgen has a number of tissue models, which include In vitro and Ex vivo models. IFN-b is offered for the treatment or prevention of asthma exacerbations caused by the common cold, and is in Clinical Phase II stage. IFN-b is provided for the treatment or prevention of COPD exacerbations caused by the common cold, and is in Clinical Phase I stage.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SNG
  • CUSIP:
Key Metrics:
  • Previous Close: $0.34
  • 50 Day Moving Average: $30.47
  • 200 Day Moving Average: $26.79
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $23.29M
  • Current Quarter EPS Consensus Estimate: $-3.57 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha